Cho James's most recent trade in Apellis Pharmaceuticals Inc was a trade of 6,250 Common Stock done . Disclosure was reported to the exchange on June 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 6,250 | 54,205 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 11,250 | 11,250 | - | - | Stock Option (Right to Buy) | |
| Gritstone Bio Inc | James Cho | SVP, CHIEF ACCOUNTING OFFICER | Other type of transaction at price $ 0.00 per share. | 04 Apr 2025 | 155,123 | 0 (0%) | 0% | 0 | Common Stock | |
| Gritstone Bio Inc | James Cho | SVP, CHIEF ACCOUNTING OFFICER | Other type of transaction at price $ 0.00 per share. | 04 Apr 2025 | 109,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Gritstone Bio Inc | James Cho | SVP, CHIEF ACCOUNTING OFFICER | Other type of transaction at price $ 0.00 per share. | 04 Apr 2025 | 65,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Gritstone Bio Inc | James Cho | SVP, CHIEF ACCOUNTING OFFICER | Other type of transaction at price $ 0.00 per share. | 04 Apr 2025 | 40,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Gritstone Bio Inc | James Cho | SVP, CHIEF ACCOUNTING OFFICER | Other type of transaction at price $ 0.00 per share. | 04 Apr 2025 | 26,300 | 0 | - | - | Stock Option (Right to Buy) | |
| Gritstone Bio Inc | James Cho | SVP, CHIEF ACCOUNTING OFFICER | Other type of transaction at price $ 0.00 per share. | 04 Apr 2025 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 24.83 per share. | 17 Mar 2025 | 183 | 47,955 (0%) | 0% | 24.8 | 4,543 | Common Stock |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.90 per share. | 28 Feb 2025 | 14,393 | 227,070 (0%) | 0% | 46.9 | 675,032 | Common Stock, $0.01 par value |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.28 per share. | 28 Feb 2025 | 3,402 | 244,176 (0%) | 0% | 46.3 | 157,445 | Common Stock, $0.01 par value |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.90 per share. | 28 Feb 2025 | 2,713 | 241,463 (0%) | 0% | 46.9 | 127,240 | Common Stock, $0.01 par value |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 22,472 | 247,578 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 26,979 | 225,106 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.32 per share. | 05 Feb 2025 | 22,451 | 219,578 (0%) | 0% | 44.3 | 995,028 | Common Stock, $0.01 par value |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2025 | 22,451 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 47.65 per share. | 05 Feb 2025 | 21,451 | 198,127 (0%) | 0% | 47.6 | 1,022,140 | Common Stock, $0.01 par value |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 30.43 per share. | 22 Jan 2025 | 1,096 | 48,138 (0%) | 0% | 30.4 | 33,346 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 12,591 | 49,234 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 29.96 per share. | 17 Jan 2025 | 715 | 36,643 (0%) | 0% | 30.0 | 21,420 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 28.70 per share. | 13 Jan 2025 | 783 | 37,358 (0%) | 0% | 28.7 | 22,474 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 36.21 per share. | 16 Sep 2024 | 192 | 38,141 (0%) | 0% | 36.2 | 6,952 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 39.49 per share. | 03 Sep 2024 | 550 | 38,333 (0%) | 0% | 39.5 | 21,720 | Common Stock |
| Gritstone Bio Inc | James Cho | SVP, CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2024 | 65,400 | 65,400 | - | - | Stock Option (Right to Buy) | |
| Gritstone Bio Inc | James Cho | SVP, CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2024 | 10,800 | 155,123 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 56.46 per share. | 15 Mar 2024 | 184 | 38,883 (0%) | 0% | 56.5 | 10,389 | Common Stock |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.70 per share. | 05 Mar 2024 | 14,823 | 197,127 (0%) | 0% | 42.7 | 632,942 | Common Stock, $0.01 par value |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.42 per share. | 02 Mar 2024 | 2,566 | 213,978 (0%) | 0% | 41.4 | 106,284 | Common Stock, $0.01 par value |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.42 per share. | 02 Mar 2024 | 2,028 | 211,950 (0%) | 0% | 41.4 | 84,000 | Common Stock, $0.01 par value |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 23,832 | 216,544 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 27,832 | 192,712 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| U.S. Bancorp. | L. James Chosy | Senior EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 40.32 per share. | 16 Feb 2024 | 21,969 | 186,462 (0%) | 0% | 40.3 | 885,790 | Common Stock, $0.01 par value |
| U.S. Bancorp. | Chosy James L. | Senior EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 21,969 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| U.S. Bancorp. | L. Chosy James | Senior EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 41.47 per share. | 16 Feb 2024 | 21,582 | 164,880 (0%) | 0% | 41.5 | 895,070 | Common Stock, $0.01 par value |
| Gritstone Bio Inc | Cho James | SVP, CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 109,000 | 109,000 | - | - | Stock Option (Right to Buy) | |
| Gritstone Bio Inc | James Cho | SVP, CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 18,000 | 138,644 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | George Chopas James | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 22 Jan 2024 | 1,061 | 39,067 (0%) | 0% | 65.0 | 68,961 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 12,086 | 12,086 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Chopas James George | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 8,312 | 40,992 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | James Chopas George | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 66.81 per share. | 16 Jan 2024 | 864 | 40,128 (0%) | 0% | 66.8 | 57,723 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 41.23 per share. | 31 Aug 2023 | 551 | 30,312 (0%) | 0% | 41.2 | 22,716 | Common Stock |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.11 per share. | 05 Mar 2023 | 2,180 | 164,493 (0%) | 0% | 47.1 | 102,700 | Common Stock, $0.01 par value |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 19,002 | 168,811 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.31 per share. | 02 Mar 2023 | 2,138 | 166,673 (0%) | 0% | 46.3 | 99,011 | Common Stock, $0.01 par value |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 5,737 | 5,737 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 4,044 | 31,197 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.50 per share. | 21 Feb 2023 | 334 | 30,863 (0%) | 0% | 58.5 | 19,539 | Common Stock |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 22,233 | 158,916 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 48.77 per share. | 09 Feb 2023 | 9,107 | 149,809 (0%) | 0% | 48.8 | 444,148 | Common Stock, $0.01 par value |
| Gritstone Bio Inc | James Cho | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 64,515 | 111,407 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.05 per share. | 20 Jan 2023 | 919 | 27,153 (0%) | 0% | 52.1 | 47,834 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 15,114 | 15,114 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 9,621 | 28,072 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.00 per share. | 20 Oct 2022 | 130 | 18,451 (0%) | 0% | 58 | 7,540 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.84 per share. | 30 Aug 2022 | 558 | 18,581 (0%) | 0% | 58.8 | 32,833 | Common Stock |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.25 per share. | 05 Mar 2022 | 2,180 | 136,683 (0%) | 0% | 55.3 | 120,445 | Common Stock, $0.01 par value |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 14,207 | 138,863 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.55 per share. | 14 Feb 2022 | 9,919 | 124,656 (0%) | 0% | 58.5 | 580,757 | Common Stock, $0.01 par value |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 21,612 | 135,881 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.75 per share. | 10 Feb 2022 | 1,306 | 134,575 (0%) | 0% | 59.8 | 78,034 | Common Stock, $0.01 par value |
| Gritstone Bio Inc | James Cho | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 26,300 | 26,300 | - | - | Stock Option (Right to Buy) | |
| Gritstone Bio Inc | James Cho | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 4,400 | 43,505 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 15,116 | 15,116 | - | - | Stock Option (right to buy) | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 10,657 | 19,139 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Oct 2021 | 882 | 8,482 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | James George Chopas | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Aug 2021 | 21,750 | 21,750 | - | - | Stock Option (right to buy) | |
| Apellis Pharmaceuticals Inc | James George Chopas | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Aug 2021 | 7,600 | 7,600 (0%) | 0% | 0 | Common Stock | |
| Gritstone Bio Inc | James Cho | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2021 | 14,484 | 114,269 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.64 per share. | 14 Feb 2021 | 9,952 | 102,342 (0%) | 0% | 47.6 | 474,113 | Common Stock, $0.01 par value |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.64 per share. | 14 Feb 2021 | 2,557 | 99,785 (0%) | 0% | 47.6 | 121,815 | Common Stock, $0.01 par value |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.61 per share. | 10 Feb 2021 | 1,315 | 112,294 (0%) | 0% | 47.6 | 62,607 | Common Stock, $0.01 par value |
| U.S. Bancorp. | James L. Chosy | Senior EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 18,954 | 113,609 (0%) | 0% | 0 | Common Stock, $0.01 par value |